Gerrit Klaerner Net Worth

The estimated Net Worth of Gerrit Klaerner is at least $20.8 Milhão dollars as of 8 December 2021. Gerrit Klaerner owns over 8,000 units of Tricida Inc stock worth over $40,717 and over the last 6 years he sold TCDA stock worth over $10,580,046. In addition, he makes $10,168,700 as President, Chief Executive Officer, e Director at Tricida Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gerrit Klaerner TCDA stock SEC Form 4 insiders trading

Gerrit has made over 36 trades of the Tricida Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,000 units of TCDA stock worth $62,720 on 8 December 2021.

The largest trade he's ever made was selling 126,000 units of Tricida Inc stock on 15 November 2021 worth over $758,520. On average, Gerrit trades about 11,118 units every 29 days since 2018. As of 8 December 2021 he still owns at least 370,157 units of Tricida Inc stock.

You can see the complete history of Gerrit Klaerner stock trades at the bottom of the page.

Gerrit Klaerner biography

Dr. Gerrit Klaerner Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Klaerner our founder, has served as a member of our board of directors since July 2013 and as our Chief Executive Officer and President since August 2013. Dr. Klaerner was a founder of Relypsa, Inc. and served as its President and as a member of its board of directors from October 2007 until June 2013. Dr. Klaerner co-founded Ilypsa, Inc. in 2003 and served as its Chief Business Officer and Senior Vice President from December 2006 until July 2007 and its Director of Technology Assessment and Business Development from January 2003 until December 2006. Dr. Klaerner served in Symyx Technologies, Inc. from October 1998 until January 2003 as Staff Scientist, Senior Staff Scientist and Director of Business Development. Dr. Klaerner received his Ph.D. in polymer and organic chemistry from the Max Planck Institute for Polymer Research in Mainz, Germany, his M.S. in Chemistry from the Philipps University of Marburg and completed post-doctoral research at Stanford University and the IBM Almaden Research Center..

What is the salary of Gerrit Klaerner?

As the President, Chief Executive Officer, e Director of Tricida Inc, the total compensation of Gerrit Klaerner at Tricida Inc is $10,168,700. There are no executives at Tricida Inc getting paid more.

How old is Gerrit Klaerner?

Gerrit Klaerner is 49, he's been the President, Chief Executive Officer, e Director of Tricida Inc since 2013. There are 12 older and 3 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.

What's Gerrit Klaerner's mailing address?

Gerrit's mailing address filed with the SEC is 7000 SHORELINE COURT, SUITE 201, , SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Tricida Inc

Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., eHealthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.

What does Tricida Inc do?

Complete history of Gerrit Klaerner stock trades at Tricida Inc

Tricida Inc executives and stock owners

Tricida Inc executives and other stock owners filed with the SEC include:

• Gerrit Klaerner,
  President, Chief Executive Officer, Director
• Dawn Parsell,
  Executive Vice President - Clinical Development
• Geoffrey Parker,
  Chief Financial Officer, Executive Vice President
• Edward Hejlek,
  Senior Vice President
• Dr. Gerrit Klaerner Ph.D.,
  Founder, Pres, CEO & Exec. Director
• Dr. Dawn Parsell Ph.D.,
  Exec. VP of Clinical Devel.
• Geoffrey M. Parker,
  COO, CFO & Exec. VP
• Robert L. McKague J.D.,
  Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
• Dr. Wilhelm Stahl,
  Exec. VP & CTO
• Klaus Veitinger,
  Independent Chairman of the Board
• David Bonita,
  Independent Director
• Kathryn Falberg,
  Independent Director
• David Hirsch,
  Independent Director
• Sandra Coufal,
  Independent Director
• Robert Alpern,
  Independent Director
• Marc Cobo,
  Senior Vice President - Finance, Chief Accounting Officer
• Robert McKague,
  Executive Vice President, General Counsel, Secretary
• Edward J. Hejlek Esq., J.D.,
  Exec. VP of Intellectual Property
• Jackie Cossmon,
  VP of Investor Relations & Communications
• Annie Yoshiyama,
  VP of Fin. & Chief Accounting Officer
• Claire Lockey,
  Chief Dev. Officer and Sr. VP
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Ven...,
  
• Beek Jeroen B Van,
  Chief Comm Officer and Sr VP
• Steffen Pietzke,
  VP Fin & Chief Acct Officer
• Capital Partners Ii, Llc Lo...,
  
• Advisors Llc Orbi Med Capit...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Wilhelm Stahl,
  EVP, Chief Tech Officer
• Brian M.Sibling Capital Ven...,
  
• Susannah Cantrell,
  EVP, Chief Comm. Officer
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Annie Yoshiyama,
  Senior VP, Finance and CAO
• Healthcare Capital Partners...,